Insulet Co. (NASDAQ:PODD) Receives $292.06 Average Price Target from Brokerages

Shares of Insulet Co. (NASDAQ:PODD - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seventeen research firms that are presently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $292.06.

PODD has been the topic of a number of research analyst reports. Canaccord Genuity Group boosted their target price on Insulet from $304.00 to $324.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Raymond James reaffirmed an "outperform" rating and set a $328.00 price objective (up from $294.00) on shares of Insulet in a report on Friday, February 21st. Wells Fargo & Company raised their target price on shares of Insulet from $305.00 to $322.00 and gave the company an "overweight" rating in a report on Friday, February 21st. TD Cowen increased their price objective on shares of Insulet from $264.00 to $324.00 and gave the company a "buy" rating in a research report on Friday, January 3rd. Finally, Stifel Nicolaus lifted their price objective on shares of Insulet from $245.00 to $293.00 and gave the stock a "hold" rating in a research note on Friday, February 21st.

Insulet Price Performance

NASDAQ PODD traded down $0.80 during trading hours on Wednesday, reaching $259.92. The company's stock had a trading volume of 276,939 shares, compared to its average volume of 712,096. Insulet has a 1 year low of $160.19 and a 1 year high of $289.46. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The company has a market capitalization of $18.25 billion, a price-to-earnings ratio of 44.92, a PEG ratio of 3.62 and a beta of 1.30. The firm's 50-day moving average price is $260.21 and its 200-day moving average price is $261.91.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping the consensus estimate of $1.00 by $0.15. The firm had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. On average, equities research analysts predict that Insulet will post 3.92 EPS for the current fiscal year.

Insider Transactions at Insulet

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of the firm's stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the transaction, the director now directly owns 3,231 shares in the company, valued at $888,525. This trade represents a 36.10 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.47% of the company's stock.

Hedge Funds Weigh In On Insulet

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Norges Bank bought a new position in Insulet during the 4th quarter worth about $248,806,000. GAMMA Investing LLC lifted its position in shares of Insulet by 27,298.6% in the 1st quarter. GAMMA Investing LLC now owns 664,141 shares of the medical instruments supplier's stock worth $1,744,100,000 after purchasing an additional 661,717 shares during the period. Raymond James Financial Inc. bought a new position in shares of Insulet during the fourth quarter valued at approximately $69,433,000. Alecta Tjanstepension Omsesidigt purchased a new position in Insulet during the fourth quarter valued at approximately $53,184,000. Finally, Artisan Partners Limited Partnership raised its stake in Insulet by 24.1% in the fourth quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier's stock worth $201,073,000 after buying an additional 149,524 shares in the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.